Cogent Biosciences Shares Outstanding History (COGT)
Cogent Biosciences reported 161.0M shares outstanding at the end of fiscal 2025.
View full Cogent Biosciences company overviewCogent Biosciences annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 161.0M | 50.5M | +45.73% |
| 2024 | 2024-12-31 | 110.5M | 24.3M | +28.26% |
| 2023 | 2023-12-31 | 86.1M | 16.2M | +23.22% |
| 2022 | 2022-12-31 | 69.9M | 26.1M | +59.55% |
| 2021 | 2021-12-31 | 43.8M | 11.5M | +35.42% |
| 2020 | 2020-12-31 | 32.3M | 24.7M | +321.98% |
| 2019 | 2019-12-31 | 7.7M | −22.4M | −74.50% |
| 2018 | 2018-12-31 | 30.1M | 19.9M | +194.64% |
| 2017 | 2017-12-31 | 10.2M | — | — |
Cogent Biosciences quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 171.6M | 57.7M | +50.62% |
| Q1 2026 | 2026-03-31 | 170.8M | 56.9M | +49.99% |
| Q4 2025 | 2025-12-31 | 161.0M | 50.5M | +45.73% |
| Q3 2025 | 2025-09-30 | 139.8M | 29.4M | +26.59% |
| Q2 2025 | 2025-06-30 | 113.9M | 4.6M | +4.19% |
| Q1 2025 | 2025-03-31 | 113.9M | 18.2M | +19.08% |
| Q4 2024 | 2024-12-31 | 110.5M | 24.3M | +28.26% |
| Q3 2024 | 2024-09-30 | 110.5M | 24.3M | +28.25% |
| Q2 2024 | 2024-06-30 | 109.3M | 24.0M | +28.14% |
| Q1 2024 | 2024-03-31 | 95.6M | 24.7M | +34.77% |
| Q4 2023 | 2023-12-31 | 86.1M | 16.2M | +23.22% |
| Q3 2023 | 2023-09-30 | 86.1M | 16.3M | +23.28% |
| Q2 2023 | 2023-06-30 | 85.3M | 19.6M | +29.87% |
| Q1 2023 | 2023-03-31 | 70.9M | 25.1M | +54.84% |
| Q4 2022 | 2022-12-31 | 69.9M | 26.1M | +59.55% |
| Q3 2022 | 2022-09-30 | 69.9M | 30.0M | +75.30% |
| Q2 2022 | 2022-06-30 | 65.7M | 25.9M | +64.97% |
| Q1 2022 | 2022-03-31 | 45.8M | 8.6M | +23.19% |
| Q4 2021 | 2021-12-31 | 43.8M | 11.5M | +35.42% |
| Q3 2021 | 2021-09-30 | 39.9M | 29.2M | +273.23% |
| Q2 2021 | 2021-06-30 | 39.8M | 8.7M | +27.82% |
| Q1 2021 | 2021-03-31 | 37.2M | 6.4M | +20.67% |
| Q4 2020 | 2020-12-31 | 32.3M | 1.7M | +5.49% |
| Q3 2020 | 2020-09-30 | 10.7M | −20.0M | −65.18% |
| Q2 2020 | 2020-06-30 | 31.2M | 501,387 | +1.64% |
| Q1 2020 | 2020-03-31 | 30.8M | 703,070 | +2.33% |
| Q4 2019 | 2019-12-31 | 30.7M | 605,084 | +2.01% |
| Q3 2019 | 2019-09-30 | 30.7M | 738,465 | +2.47% |
| Q2 2019 | 2019-06-30 | 30.7M | 793,306 | +2.66% |
| Q1 2019 | 2019-03-31 | 30.1M | 19.9M | +195.05% |
| Q4 2018 | 2018-12-31 | 30.1M | 19.9M | +194.64% |
| Q3 2018 | 2018-09-30 | 29.9M | — | — |
| Q2 2018 | 2018-06-30 | 29.9M | — | — |
| Q1 2018 | 2018-03-31 | 10.2M | — | — |
| Q4 2017 | 2017-12-31 | 10.2M | — | — |
Cogent Biosciences shares outstanding trends
Over the last five reported fiscal years, Cogent Biosciences's shares outstanding moved from 32.3M to 161.0M, a change of 128.6M. The latest reported quarter, Q2 2026, shows 171.6M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cogent Biosciences filings at SEC.gov ↗